Stocks and Investing Stocks and Investing
Wed, November 3, 2021

Brian Abrahams Maintained (VRTX) at Buy with Increased Target to $250 on, Nov 3rd, 2021


Published on 2024-10-27 18:28:59 - WOPRAI, Brian Abrahams
  Print publication without navigation


Brian Abrahams of RBC Capital, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $246 to $250 on, Nov 3rd, 2021.

Brian has made no other calls on VRTX in the last 4 months.



There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 1 agrees with Brian's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $213 on, Thursday, September 9th, 2021


These are the ratings of the 5 analyists that currently disagree with Brian


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Tuesday, November 2nd, 2021
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Tuesday, October 19th, 2021
  • Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell and Held Target at $202 on, Tuesday, September 7th, 2021
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $323 on, Friday, July 30th, 2021
  • Geoffrey Porges of "SVB Leerink" Maintained at Sell with Increased Target to $175 on, Friday, July 30th, 2021
Contributing Sources